Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Work and productivity loss in the rizatriptan multiple attack study.

E J Dasbach1, G W Carides, W C Gerth

  • 1Merck & Co, Inc, Blue Bell, PA 19422, USA. erik_dasbach@merck.com

Cephalalgia : an International Journal of Headache
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

BJOG : an international journal of obstetrics and gynaecology·2008
Same author

Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes.

International journal of clinical practice·2005
Same author

Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

Journal of human hypertension·2004
Same author

Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.

International journal of clinical practice·2003
Same author

A regression-based method for estimating mean treatment cost in the presence of right-censoring.

Biostatistics (Oxford, England)·2003
Same author

Determinants of migraine-specific quality of life.

Cephalalgia : an international journal of headache·2002
Same journal

Burning mouth syndrome and oral dysaesthetic/perceptual symptoms: Toward clinically actionable boundaries.

Cephalalgia : an international journal of headache·2026
Same journal

Effectiveness and clinical predictors of rimegepant for acute vertigo in vestibular migraine: A real-world cohort study.

Cephalalgia : an international journal of headache·2026
Same journal

Efficacy of digital therapeutic sinCephalea for personalised nutrition versus control for migraine prevention: A 12-week open-label randomised clinical trial.

Cephalalgia : an international journal of headache·2026
Same journal

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

Cephalalgia : an international journal of headache·2026
Same journal

Placebo or active comparator in chronic migraine trials: Balancing evidence and practicality.

Cephalalgia : an international journal of headache·2026
Same journal

Impaired bone status in high frequency episodic or chronic migraine women: A case-control study with blood and densitometric parameters.

Cephalalgia : an international journal of headache·2026
See all related articles

Rizatriptan treatment significantly reduced work loss and improved productivity in patients with acute migraine. This migraine medication decreased absenteeism and enhanced on-the-job effectiveness, benefiting employed individuals.

Area of Science:

  • Neurology
  • Pharmacology
  • Occupational Health

Background:

  • Migraine significantly impacts work productivity and causes absenteeism.
  • Quantifying the economic burden of migraine on paid work is crucial.

Purpose of the Study:

  • To measure the self-reported effect of acute migraine and its treatment on paid work and productivity loss.
  • To assess the impact of rizatriptan on migraine-related work absenteeism and productivity.

Main Methods:

  • A randomized, double-blind, placebo-controlled, crossover study.
  • 407 patients aged 18-65 with moderate to severe migraines completed a self-administered questionnaire.
  • Patients treated four separate migraine attacks with either rizatriptan 10 mg or placebo.

Related Experiment Videos

Main Results:

  • Rizatriptan use was associated with 0.7 fewer hours of absenteeism and 0.4 fewer hours of lost productive time per attack compared to placebo (P < 0.01).
  • Total work loss per migraine attack was reduced by 1.1 hours with rizatriptan versus placebo (P < 0.01).
  • Rizatriptan significantly decreased migraine-related work loss and improved on-the-job effectiveness.

Conclusions:

  • Rizatriptan effectively reduces the impact of acute migraine on paid work and productivity.
  • Treatment with rizatriptan can mitigate economic losses associated with migraine absenteeism and reduced work effectiveness.